## Claudia Ciano

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1123589/publications.pdf

Version: 2024-02-01

172457 223800 2,428 77 29 46 citations h-index g-index papers 77 77 77 3083 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, The, 2011, 10, 320-328.	10.2	222
2	Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain, 2014, 137, 1907-1920.	7.6	133
3	Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology, 1996, 46, 1133-1137.	1.1	118
4	Infantile neuroaxonal dystrophy. Neurology, 1999, 52, 1472-1472.	1.1	108
5	Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology, 2000, 54, 1696-1698.	1.1	84
6	Myoclonus–dystonia syndrome: Clinical presentation, disease course, and genetic features in 11 families. Movement Disorders, 2008, 23, 28-34.	3.9	75
7	Amyotrophic lateral sclerosis causes small fiber pathology. European Journal of Neurology, 2016, 23, 416-420.	3.3	65
8	Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurological Sciences, 2000, 21, 31-37.	1.9	62
9	Supratentorial and pontine <scp>MRI</scp> abnormalities characterize recessive spastic ataxia of <scp>C</scp> harlevoixâ€ <scp>S</scp> aguenay. A comprehensive study of an <scp>I</scp> talian series. European Journal of Neurology, 2013, 20, 138-146.	3.3	57
10	Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscular Disorders, 2008, 18, 19-26.	0.6	55
11	Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG–EMG relationship estimated using autoregressive models. Clinical Neurophysiology, 2003, 114, 1041-1052.	1.5	54
12	Sensorimotor cortex excitability in Unverricht–Lundborg disease and Lafora body disease. Neurology, 2004, 63, 2309-2315.	1.1	50
13	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	7.1	47
14	Responsiveness of clinical outcome measures in Charcotâ^'Marieâ^'Tooth disease. European Journal of Neurology, 2015, 22, 1556-1563.	3.3	47
15	Nerve conduction velocity in <scp>CMT</scp> 1A: what else can we tell?. European Journal of Neurology, 2016, 23, 1566-1571.	3.3	45
16	Painful neuropathy in subclinical hypothyroidism: clinical and neuropathological recovery after hormone replacement therapy. Neurological Sciences, 2009, 30, 149-151.	1.9	44
17	The G389R mutation in the <i>MAPT</i> gene presenting as sporadic corticobasal syndrome. Movement Disorders, 2008, 23, 892-895.	3.9	43
18	A neurophysiological study of myoclonus in patients with DYT11 myoclonusâ€dystonia syndrome. Movement Disorders, 2008, 23, 2041-2048.	3.9	43

#	Article	IF	Citations
19	Adult onset myoclonic Huntington's disease. Movement Disorders, 1993, 8, 201-205.	3.9	42
20	Subclinical leukodystrophy and infertility in a man with a novel homozygous <i>CLCN2</i> mutation. Neurology, 2014, 83, 1217-1218.	1.1	42
21	HMSN III phenotype due to homozygous expression of a dominant HMSN II gene. Neurology, 1992, 42, 2201-2201.	1.1	42
22	Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 410-415.	2.1	41
23	Phenomenology of psychogenic movement disorders in children. Movement Disorders, 2012, 27, 1153-1157.	3.9	39
24	Myoclonic dystonia as unique presentation of isolated vitamin E deficiency in a young patient. Movement Disorders, 2002, 17, 612-614.	3.9	36
25	Myoclonus in corticobasal degeneration. Movement Disorders, 1997, 12, 598-603.	3.9	35
26	Exteroceptive reflexes in dystonia: A study of the recovery cycle of the R2 component of the blink reflex and of the exteroceptive suppression of the contracting sternocleidomastoid muscle in blepharospasm and torticollis. Movement Disorders, 2004, 9, 183-187.	3.9	35
27	Detection of hereditary neuropathy with liability to pressure palsies among patients with acute painless mononeuropathy or plexopathy., 1998, 21, 1686-1691.		34
28	PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain, 2014, 137, 1614-1620.	7.6	33
29	Screening for <i>SH3TC2</i> gene mutations in a series of demyelinating recessive Charcotâ€Marieâ€Tooth disease (CMT4). Journal of the Peripheral Nervous System, 2016, 21, 142-149.	3.1	32
30	Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Research, 2010, 89, 232-237.	1.6	31
31	Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia. Neurology, 2005, 64, 1290-1293.	1.1	30
32	Celiac disease presenting with motor neuropathy: Effect of gluten free-diet. Muscle and Nerve, 2007, 35, 675-677.	2.2	27
33	Neurophysiological features in relation to clinical signs in clinically diagnosed corticobasal degeneration. Neurological Sciences, 2003, 24, 16-23.	1.9	26
34	Movement-related desynchronization-synchronization (ERD/ERS) in patients with Unverricht–Lundborg disease. Neurolmage, 2006, 33, 161-168.	4.2	26
35	POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation. Neuromuscular Disorders, 2007, 17, 980-982.	0.6	25
36	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017.	0.6	25

#	Article	IF	CITATIONS
37	Characterization of severe action myoclonus in sialidoses. Epilepsy Research, 2011, 94, 86-93.	1.6	24
38	Novel mutations in the GDAP1 gene in patients affected with early-onset axonal Charcot-Marie-Tooth type 4A. Neuromuscular Disorders, 2009, 19, 476-480.	0.6	23
39	Mutational mechanisms in <i><scp>MFN2</scp></i> i>â€related neuropathy: compound heterozygosity for recessive and semidominant mutations. Journal of the Peripheral Nervous System, 2015, 20, 380-386.	3.1	23
40	Abnormal lysosomal and ubiquitin-proteasome pathways in 19p13.3 distal myopathy. Annals of Neurology, 2004, 56, 133-138.	5.3	22
41	Rhythmic cortical myoclonus in Niemann-Pick disease type C. Movement Disorders, 2006, 21, 1453-1456.	3.9	22
42	Cortical myoclonus in childhood and juvenile onset Huntington's disease. Parkinsonism and Related Disorders, 2012, 18, 794-797.	2.2	22
43	Does CMT1A homozygosity cause more severe disease with root hypertrophy and higher CSF proteins?. Neurology, 2003, 60, 1721-1722.	1.1	21
44	Xâ€linked Charcotâ€Marieâ€Tooth type 1: strokeâ€like presentation of a novel <i><scp>GJB1</scp></i> mutation. Journal of the Peripheral Nervous System, 2014, 19, 183-186.	3.1	20
45	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. Italian Journal of Neurological Sciences, 1994, 15, 333-340.	0.1	19
46	Heterozygous Null Mutation in the P O Gene Associated with Mild Charcot-Marie-Tooth Disease. Annals of the New York Academy of Sciences, 1999, 883, 477-480.	3.8	19
47	Co-occurrence of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease type 2A in a patient with a novel mutation in the mitofusin-2 gene. Neuromuscular Disorders, 2011, 21, 129-131.	0.6	19
48	Progressive dysarthria: definition and clinical follow-up. Neurological Sciences, 2003, 24, 211-212.	1.9	18
49	Unrecognized Charcot-Marie-Tooth Disease. Anesthesia and Analgesia, 1995, 81, 199-201.	2.2	17
50	Hypo- and Hypersensitivity to Vecuronium in a Patient with Guillain-Barr?? Syndromem. Anesthesia and Analgesia, 1994, 78, 187???189.	2.2	16
51	Propriospinal myoclonus with life threatening tonic spasms as paraneoplastic presentation of breast cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 422-424.	1.9	15
52	Giant SEPs and SEP-recovery function in Unverricht–Lundborg disease. Clinical Neurophysiology, 2013, 124, 1013-1018.	1.5	15
53	Hand function assessment in the first years of life in unilateral cerebral palsy: Correlation with neuroimaging and cortico-spinal reorganization. European Journal of Paediatric Neurology, 2016, 20, 114-124.	1.6	15
54	Rhythmic cortical myoclonus in a case of HIV-related encephalopathy. Movement Disorders, 2003, 18, 1533-1538.	3.9	14

#	Article	IF	Citations
55	Hypomyelinating leukodystrophies in adults: Clinical and genetic features. European Journal of Neurology, 2021, 28, 934-944.	3.3	14
56	Childhood-onset multifocal motor neuropathy with conduction blocks. Neurology, 2006, 66, 922-924.	1.1	13
57	Polymyography in the diagnosis of childhood onset movement disorders. European Journal of Paediatric Neurology, 2008, 12, 480-483.	1.6	11
58	Sleepâ€related tongue biting may not be a sign of epilepsy: A case of sleepâ€related faciomandibular myoclonus. Epilepsia, 2009, 50, 157-159.	5.1	11
59	Combined central and peripheral acute demyelination. Italian Journal of Neurological Sciences, 1993, 14, 83-86.	0.1	10
60	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1281-1290.	1.9	9
61	Unexpected Right Phrenic Nerve Injury During 5-Fluorouracil Continuous Infusion Plus Cisplatin and Vinorelbine in Breast Cancer Patients. Journal of the National Cancer Institute, 2000, 92, 755-755.	6.3	8
62	Hereditary gelsolin amyloidosis ( <scp>HGA</scp> ): a neglected cause of bilateral progressive or recurrent facial palsy. Journal of the Peripheral Nervous System, 2017, 22, 59-63.	3.1	8
63	Peripheral nerve conduction velocity in normal infants and children. Italian Journal of Neurological Sciences, 1989, 10, 311-314.	0.1	6
64	Lower limb areflexia without central and peripheral conduction abnormalities is highly suggestive of Gerstmann–StrÃ <b>¤</b> ssler–Scheinker disease Pro102Leu. Journal of the Neurological Sciences, 2011, 302, 85-88.	0.6	6
65	Doubleâ€ŧrouble in pediatric neurology: Myotonia congenita combined with charcot–marie–tooth disease type 1a. Muscle and Nerve, 2014, 50, 145-147.	2.2	6
66	A novel <i><scp>NDRG1</scp></i> mutation in a nonâ€Romani patient with <scp>CMT4D</scp> / <scp>HMSN</scp> â€Lom. Journal of the Peripheral Nervous System, 2017, 22, 47-50.	3.1	6
67	High-Frequency Rhythmic Cortical Myoclonus in a Long-Surviving Patient With Nonketotic Hypergylcemia. Journal of Child Neurology, 2008, 23, 321-324.	1.4	4
68	Expanding the phenotypic spectrum of TRIM2 â€associated Charcotâ€Marieâ€Tooth disease. Journal of the Peripheral Nervous System, 2020, 25, 429-432.	3.1	4
69	A Case of Severe Early-Onset Neuropathy Caused by a Compound Heterozygous Deletion of the PMP22 Gene: Clinical and Neurographic Aspects. Neuropediatrics, 2020, 51, 173-177.	0.6	3
70	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. BMJ Case Reports, 2009, 2009, bcr0920080988-bcr0920080988.	0.5	3
71	Unrecognized Charcot-Marie-Tooth Disease. Anesthesia and Analgesia, 1995, 81, 199-201.	2.2	2
72	Intrathecal immune activation in three patients with progressive myoclonic ataxia. Movement Disorders, 1995, 10, 207-210.	3.9	2

#	Article	IF	CITATIONS
73	Monomelic amyotrophy in cervical myelopathy associated with anterior dural sac displacement induced by neck flexion. Journal of Neurology, 2016, 263, 823-825.	3.6	2
74	Spasmodic dystonic laterocollis in familial cerebellar ataxia. Italian Journal of Neurological Sciences, 1994, 15, 245-248.	0.1	1
75	Coexistence of Charcotâ€Marieâ€Tooth disease type 1A and antiâ€MAG neuropathy. Journal of the Peripheral Nervous System, 2013, 18, 185-188.	3.1	1
76	Childhood onset of acquired neuromyotonia: Association with a ganglioneuroma. Muscle and Nerve, 2015, 51, 620-621.	2.2	1
77	Acute dyspnea due to right phrenic palsy during infusional chemotherapy. Annals of Oncology, 2004, 15, 691-692.	1.2	O